Equities Analysts Set Expectations for MNMD Q1 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Mind Medicine (MindMed) in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman forecasts that the company will earn ($0.35) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMD) last issued its earnings results on Thursday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. During the same quarter in the prior year, the firm posted ($0.53) earnings per share.

Other research analysts have also recently issued research reports about the stock. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a research report on Tuesday. They issued an “outperform” rating and a $23.00 target price for the company. Chardan Capital began coverage on Mind Medicine (MindMed) in a research note on Friday, December 20th. They issued a “buy” rating and a $20.00 price target for the company. Oppenheimer restated an “outperform” rating and set a $20.00 price objective on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Monday, November 11th. Finally, Leerink Partners initiated coverage on shares of Mind Medicine (MindMed) in a research note on Monday, October 14th. They set an “outperform” rating and a $20.00 target price on the stock. Ten investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $26.33.

Mind Medicine (MindMed) Price Performance

Shares of MNMD opened at $7.13 on Thursday. The stock has a fifty day moving average price of $7.28 and a 200 day moving average price of $6.94. The company has a market cap of $522.84 million, a P/E ratio of -3.15 and a beta of 2.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. Mind Medicine has a 12 month low of $3.82 and a 12 month high of $12.22.

Insiders Place Their Bets

In related news, CEO Robert Barrow sold 19,106 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $7.43, for a total value of $141,957.58. Following the completion of the sale, the chief executive officer now directly owns 526,666 shares of the company’s stock, valued at approximately $3,913,128.38. This represents a 3.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dan Karlin sold 6,643 shares of Mind Medicine (MindMed) stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $49,357.49. Following the transaction, the insider now directly owns 338,013 shares in the company, valued at approximately $2,511,436.59. This trade represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,022 shares of company stock worth $208,203. Company insiders own 2.26% of the company’s stock.

Institutional Trading of Mind Medicine (MindMed)

Institutional investors have recently bought and sold shares of the company. Barclays PLC grew its stake in shares of Mind Medicine (MindMed) by 203.6% in the 3rd quarter. Barclays PLC now owns 136,098 shares of the company’s stock valued at $775,000 after buying an additional 91,271 shares in the last quarter. Wellington Management Group LLP grew its position in Mind Medicine (MindMed) by 142.6% in the third quarter. Wellington Management Group LLP now owns 185,722 shares of the company’s stock worth $1,057,000 after acquiring an additional 109,152 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Mind Medicine (MindMed) by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company’s stock worth $9,548,000 after purchasing an additional 162,933 shares during the last quarter. State Street Corp raised its holdings in shares of Mind Medicine (MindMed) by 0.5% during the 3rd quarter. State Street Corp now owns 1,814,829 shares of the company’s stock valued at $10,326,000 after purchasing an additional 9,782 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Mind Medicine (MindMed) by 21.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,430 shares of the company’s stock valued at $87,000 after purchasing an additional 2,230 shares during the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.